Weekly Recap: HC Wainwright $38 target and advances two ctDNA MRD programs

HC Wainwright lifted its price target on Biodesix, Inc. (NASDAQ:BDSX) to $38 from $27, citing a richer diagnostics multiple and confidence in the company’s MRD testing strategy as BDSX advances tumor—informed and tumor—naïve ctDNA programs with Bio—Rad and Thermo Fisher toward MSK validation and pa…